Price movement over the last 24 hours
Agilent Technologies Inc vs Manulife Financial Corporation — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Manulife Financial Corporation trades at $41.08 (market cap $68.99B). The key difference: Manulife Financial Corporation is the larger of the two by market cap, and Manulife Financial Corporation pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| A | MFC | |
|---|---|---|
Market Cap | $37.04B | $68.99B |
Sector | Health | Financials |
52-Week High | $157.20 | $41.40 |
52-Week Low | $110.24 | $29.90 |
Enterprise Value | $38.59B | $65.55B |
Dividend Yield | 0.78% | 3.22% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Manulife Financial (MFC) trades at $41.40, up 0.53% today, with a bullish technical signal from moving averages and strong analyst support (57% buy ratings). Recent Q1 2026 earnings missed expectations, but revenue grew to $53.01B in 2025, with net income of $5.78B. The company maintains a solid dividend, with a $0.49 payment scheduled for June 2026, and has demonstrated consistent operational cash flow growth, reaching $32.11B in 2025.
MFC's outlook is positive due to its AI initiatives and Asia growth, but risks include regulatory scrutiny and Q1 earnings miss. The stock's P/E of 16.92 and ROE of 13.14% suggest reasonable valuation, though investors should monitor debt levels and competitive pressures in insurance markets for sustained performance.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →